Key result
In a pharmacoeconomic model of patients with von Willebrand disease, regular preventative administration of Wilate reduced costs and resulted in fewer hemorrhages (1.40 per month) compared to Haemate P (1.93) and Immunate (1.88).
Why the study?
Does Wilate reduce costs and provide effective hemostasis compared to older generation products in patients with von Willebrand disease?
Does Wilate reduce costs and provide effective hemostasis compared to older generation products in patients with von Willebrand disease?
Wilate may offer a cost-effective treatment option for von Willebrand disease compared to older generation factor concentrates.
Answers are grounded in this paper and cite their sources.
High reported hemostatic efficacy across concentrates may guide vWD management; leaves open standardized comparative cost-effectiveness analyses.
The aim of this study was to determine optimal medical technique based on assessing cost and efficacy of treatment of von Willebrand disease using blood clotting factor concentrates (blood clotting factor VIII + von Willebrand factor): Wilate, Haemate P, Immunate.It was determined that in studies on assessing the efficiency of the concentrates more than 95% of patients rated hemostasis excellent/good.However, the studies were based on different scales of efficiency assessment, different vWF:RСo doses and different data for vWD patients (severity of the disease), therefore the efficiency of blood clotting factor concentrates might be not equal.Results of present study with the assumption about equality of groups, that were analyzed in studies on assessing the efficiency of the concentrates (although, studies on Wilate included more severe patients),evidence that prescribing blood clotting factor concentrate Wilate lead to cost savings compared to the older generation products.
No takes yet. Share an insight, caveat, or question.
Kulikov et al. (2015) studied von Willebrand disease (n=1,491). Wilate vs. Haemate P and Immunate was evaluated on Number of hemorrhages during prophylaxis treatment per month. In a pharmacoeconomic model of patients with von Willebrand disease, regular preventative administration of Wilate reduced costs and resulted in fewer hemorrhages (1.40 per month) compared to Haemate P (1.93) and Immunate (1.88).
Synapse has enriched 10 related papers. Consider them for comparative context: